11 completed, 4 terminated, 1 recruiting, 1 withdrawn. 7 Phase 1, 5 Phase 2, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 3 | 5 | Terminated 3, Completed 2 |
Follow this drug Literature Review of Aticaprant trials Research Report on Aticaprant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia Aticaprant, Placebo - Schizophrenia | Phase 1 | Recruiting | Janssen Research & Development, LLC | 64 | 2026-03-02 | 2026-09-28 |
| A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure Aticaprant, Placebo - Depressive Disorder, Major, Anhedonia | Phase 3 | Terminated | Janssen Research & Development, LLC | 47 | 2024-09-19 | 2026-06-08 |
| A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant Aticaprant, Placebo - Depressive Disorder, Major, Anhedonia | Phase 3 | Terminated | Janssen Research & Development, LLC | 101 | 2024-06-26 | 2026-02-17 |
| A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy Aticaprant, Placebo - Depressive Disorder, Major, Anhedonia | Phase 3 | Completed | Janssen Research & Development, LLC | 444 | 2022-12-06 | 2026-02-13 |
| A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) Aticaprant - Depressive Disorder, Major | Phase 3 | Terminated | Janssen Research & Development, LLC | 871 | 2022-09-22 | 2026-10-06 |
| A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy Aticaprant, Placebo - Depressive Disorder, Major, Anhedonia | Phase 3 | Completed | Janssen Research & Development, LLC | 513 | 2022-06-22 | 2025-11-06 |
| A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants Aticaprant Supratherapeutic Dose, Aticaprant Therapeutic Dose, Placebo - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 60 | 2022-05-30 | 2025-04-27 |
| A Study of 14C JNJ-67953964 in Healthy Adult Male Participants 14C-aticaprant - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 8 | 2022-01-14 | 2025-04-27 |
| A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants JNJ-67953964, Placebo - Healthy | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 30 | 2021-04-30 | 2025-04-28 |
| A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants JNJ-67953964, Placebo - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 76 | 2019-12-17 | 2025-04-27 |
| A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression JNJ-67953964, Placebo - Depressive Disorder, Major | Phase 2 | Completed | Janssen Research & Development, LLC | 181 | 2018-07-16 | 2025-04-29 |
| Does CERC-501 Attenuate Stress-precipitated Smoking Lapse? CERC-501, Placebo - Smoking | Phase 2 | Completed | Yale University | 17 | 2016-06-30 | 2019-08-13 |
| A Study in a Human Laboratory Model of Smoking Behavior CERC-501, Placebo - Smoking | Phase 2 | Completed | Janssen Research & Development, LLC | 71 | 2015-12-31 | 2025-04-27 |
| Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a CERC-501, placebo - ANXIETY DISORDERS (or Anxiety and Phobic Neuroses) | Phase 2 | Completed | Duke University | 163 | 2015-06-01 | 2019-01-08 |
| FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 Study LY2456302 - Anxiety Disorders | Phase 1 | Withdrawn | Andrew Krystal | 2014-10-01 | 2015-05-28 | |
| Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression CERC-501, Placebo - Treatment Resistant Depression | Phase 2 | Terminated | Massachusetts General Hospital | 8 | 2013-09-12 | 2017-07-02 |
| A Study of Brain Receptor Occupancy in Healthy Subjects opioid receptor kappa antagonist - Alcohol Dependence | Phase 1 | Completed | Eli Lilly and Company | 13 | 2010-12-01 | 2011-05-09 |
Depressive Disorder, Major (7) · Anhedonia (6) · Anxiety Disorders (2) · Smoking (2) · Alcoholism (1) · Depression (1) · Depressive Disorder, Treatment-Resistant (1) · Phobic Disorders (1) · Schizophrenia (1)
Janssen Research & Development, LLC (11) · Andrew Krystal (1) · Duke University (1) · Eli Lilly and Company (1) · Janssen Pharmaceutical K.K. (1) · Massachusetts General Hospital (1) · Yale University (1)
United States (13) · Belgium (6) · Brazil (5) · Bulgaria (5) · Poland (5) · Argentina (4) · Spain (4) · Czechia (3) · France (3) · Hungary (3) · Sweden (3) · United Kingdom (3) · Australia (2) · Canada (2) · China (2)
Andrew D Krystal, MD, MS (1) · John Zajecka, MD (1) · Linda L Carpenter, MD (1) · Mary F Morrison, MD (1) · Matthew Macaluso, DO (1) · Maurizio Fava, MD (1) · Richard D Weiner, MD, PhD (1) · Ronald Marcus, MD (1) · Sherry McKee, PhD (1)
2019 (2), 2023 (1), 271201100006I-0-27100007-1 (1), P50DA033945 (1)